Medicine & Life Sciences
1-(2-(1H-benzo(d)imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
6%
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
23%
Acute Myeloid Leukemia
66%
Acute Promyelocytic Leukemia
6%
Allogeneic Cells
8%
asciminib
6%
Azacitidine
6%
B-Cell Chronic Lymphocytic Leukemia
7%
Blast Crisis
12%
Bone Marrow
8%
bosutinib
15%
Chromosome Aberrations
7%
Clinical Trials
5%
Clofarabine
6%
Cyclophosphamide
7%
Cytarabine
26%
Cytogenetics
31%
Dasatinib
28%
Decitabine
9%
Drug Therapy
11%
fludarabine
8%
GATA2 Deficiency
9%
Gemtuzumab
7%
Hematologic Neoplasms
8%
Homoharringtonine
8%
Idarubicin
9%
Imatinib Mesylate
80%
Interferons
5%
Leukemia
24%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
100%
Leukemia, Myeloid, Chronic Phase
52%
Leukemia, Myelomonocytic, Chronic
6%
Mutation
16%
Myelodysplastic Syndromes
25%
Neoplasms
8%
Philadelphia Chromosome
30%
Phosphotransferases
10%
Polycythemia Vera
5%
ponatinib
11%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24%
Primary Myelofibrosis
16%
Progression-Free Survival
7%
Protein-Tyrosine Kinases
47%
Recurrence
7%
Safety
9%
Stem Cell Transplantation
7%
Survival
25%
Survival Rate
5%
Therapeutics
23%
Vincristine
6%